Theralase Developing Next Generation Medical Lasers
25 Mars 2014 - 11:59AM
Access Wire
Toronto, Ontario / ACCESSWIRE / March 25, 2014 / Theralase
Technologies Inc. (TSXV: TLT) (TLTFF: OTCBB) announced today the
expansion of its engineering team to develop and commercialize its
next generation of smart medical laser technologies. This highly
trained engineering team will be instrumental in developing
Theralase products to eliminate pain and heal tissue, a $100
Billion industry in the US and to destroy cancer, a $77 Billion
industry in the US.
The first of these cutting-edge technologies under development
is the patented TLC-2000, a technology that eliminates pain by
automatically adjusting its laser parameters in direct relation to
a patient's condition and their physical characteristics allowing
the delivery of an optimized laser treatment, specific to a
particular patient, each and every time. This dramatic advancement
in pain medicine will allow much more effective patient specific
treatments than currently available and also provide valuable
treatment feedback information to the practitioner to further
enhance the effectiveness of their patient's treatments. The second
cutting-edge technology under development is the TLC-3000
anti-cancer medical laser, a patient specific cancer solution,
which is able to deliver a specific dose of laser light through
fibre optic bundles directly to cancerous tissues. The technology
will be specifically designed to destroy tumours, wherever they may
reside in the body, by activating patented Photo Dynamic Compounds
(PDCs), already previously disclosed by the Company to be extremely
effective in the destruction of cancer.
The newly expanded engineering team, managed by Wayne Embree, a
senior engineering manager, who has been involved in leading
engineering teams in the design and development of complex
electronic technologies over the past 38 years. His team consists
of 5 full time and 4 consultant engineering personnel, who are all
resident experts in their respective fields of hardware, software,
firmware and radio frequency communication design.
Mr. Embree, VP Engineering for Theralase, stated, "I am excited
to join Theralase and be associated with some of the leading minds
in engineering, chemistry, biology, physics and medicine to develop
the next generation of medical laser technology. The technology
they have amassed to date is ground breaking and with its
commercialization in the next few years, they will undoubtedly
introduce to main stream medicine truly disruptive technology,
which will have a dramatic effect on the way medicine is practiced
for years to come."
Dr. Arkady Mandel, Chief Scientific Officer of Theralase stated
that, "Wayne's strong engineering background coupled with my
in-depth scientific and medical knowledge in how laser light
interacts at the molecular, cellular and tissue levels in the human
body, will bring a whole new platform of cutting-edge laser
technologies to the forefront in the next few years."
Roger Dumoulin-White, President and CEO of Theralase stated
that, "I am delighted that Wayne has joined the Theralase
management team and am confident in his ability to commercialize
the next generation medical laser technologies. His skill set will
be an asset to the corporation as we launch these disruptive
technologies, allowing the Company an ability to significantly
increase its revenues."
About Theralase Technologies Inc.
Theralase Technologies Inc. designs, manufactures and markets
patented, superpulsed laser technology used in eliminating pain and
destroying cancer. Theralase technology is safe and effective in
eliminating pain, reducing inflammation and accelerating tissue
regeneration of numerous nerve, muscle and joint injuries.
Theralase is actively developing patented technology that is able
to target and destroy cancers, bacteria and viruses when light
activated.
Additional information is available at www.theralase.com and
www.sedar.com .
This press release contains forward-looking statements, which
reflect the Company's current expectations regarding future events.
The forward-looking statements involve risks and uncertainties.
Actual results could differ materially from those projected herein.
The Company disclaims any obligation to update these
forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchanges) accepts responsibility for the adequacy or
accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
1-866-THE-LASE (843-5273)
416-699-LASE (5273) ext. 225
rwhite@theralase.com
SOURCE: Theralase Technologies Inc.
Theralase Technologies (TSXV:TLT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Theralase Technologies (TSXV:TLT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024